Qube Research & Technologies (QRT)’s PTC Therapeutics PTCT Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$25.4M	Sell	311,374 -202,449	-39%	-$14.6M	0.02%	805
2026 Q1	$35M	Buy	+513,823	New	+$36.4M	0.04%	578
2025 Q4	–	Sell	-430,934	Closed	-$26.4M	–	4000
2025 Q3	$26.4M	Buy	430,934 +92,771	+27%	+$4.83M	0.03%	760
2025 Q2	$16.5M	Buy	338,163 +41,596	+14%	+$1.97M	0.02%	988
2025 Q1	$15.1M	Buy	296,567 +66,436	+29%	+$3.32M	0.02%	882
2024 Q4	$10.4M	Buy	230,131 +145,382	+172%	+$6.22M	0.01%	1064
2024 Q3	$3.14M	Buy	+84,749	New	+$2.84M	﹤0.01%	1586
2024 Q2	–	Sell	-31,438	Closed	-$915K	–	4534
2024 Q1	$915K	Buy	+31,438	New	+$881K	﹤0.01%	2192
2023 Q4	–	Sell	-10,476	Closed	-$235K	–	4656
2023 Q3	$235K	Buy	+10,476	New	+$390K	﹤0.01%	2340
2022 Q4	–	Sell	-41,654	Closed	-$2.09M	–	2891
2022 Q3	$2.09M	Buy	+41,654	New	+$2.04M	0.01%	915
2021 Q2	–	Sell	-13,066	Closed	-$619K	–	2696
2021 Q1	$619K	Buy	13,066 +4,227	+48%	+$251K	0.01%	1062
2020 Q4	$539K	Buy	+8,839	New	+$521K	0.01%	1086
2020 Q1	–	Sell	-6,000	Closed	-$288K	–	1551
2019 Q4	$288K	Buy	+6,000	New	+$255K	0.01%	1239

Other funds holding PTCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Qube Research & Technologies (QRT)'s PTCT Position: Q2 2026 in Review

Qube Research & Technologies (QRT) reduced its PTC Therapeutics (PTCT) stake by 39% in Q2 2026, selling an estimated $14.6M and leaving 311,374 shares worth $25.4M. The position accounts for 0.02% of the portfolio, ranked #805.

Qube Research & Technologies (QRT) first reported a position in PTCT in Q4 2019 and has held it in 13 quarters since. The position peaked at $35M in Q1 2026. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

Qube Research & Technologies (QRT) held 311,374 shares of PTC Therapeutics worth $25.4M as of Q2 2026.
Qube Research & Technologies (QRT) sold 202,449 PTC Therapeutics shares in Q2 2026, an estimated $14.6M.
PTC Therapeutics made up 0.02% of Qube Research & Technologies (QRT)'s portfolio in Q2 2026, its #805 holding.
Qube Research & Technologies (QRT) first reported a position in PTC Therapeutics in Q4 2019 and has held it in 13 quarters since.
Qube Research & Technologies (QRT)'s PTC Therapeutics position peaked at $35M in Q1 2026.
382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.